glucocorticoid-induced osteoporosis
Conditions
Sponsors
Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with rheumatic diseases taking prednisolone 2.5 mg/day or more and receiving denosumab for at least 1 year, and 40 years of age or older with low bone mineral density 2) Patients with a T-score of -2.0 or less in bone mineral density of the lumbar spine, femoral neck or total hip by DEXA. 3) Patients with a history of fragility fracture. 4) Patients with a probability of major osteoporotic fracture greater than or equal to 20% or a probability of proximal femoral fracture greater than or equal to 3% at 10 years by FRAX. 5) Patients who have provided written informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients with contraindications to romosozumab or denosumab 2) Patients with active infection or malignancy 3) Patients who are currently pregnant, lactating, or willing to get pregnant 4) Patients who do not give consent to this study 5) Patients previously treated with romosozumab or teriparatide
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percent change of bone mineral density of the lumbar spine (L2-4), femoral neck and total hip at 52 and 104 weeks in the romosozumab and teriparatide groups. | — |
Countries
Japan
Contacts
Public ContactMai Kawazoe
Toho University School of Medicine Division of Rheumatology, Department of Internal Medicine
Outcome results
None listed